Acurx Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Acurx Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Acurx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.82M, a 9.42% increase year-over-year.
  • Acurx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$16.4M, a 29.2% decline year-over-year.
  • Acurx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$14.6M, a 20.5% decline from 2022.
  • Acurx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$12.1M, a 5.14% increase from 2021.
  • Acurx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.7M, a 177% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$16.4M -$2.82M +$293K +9.42% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$16.7M -$4.12M -$677K -19.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$16.1M -$4.38M -$1.47M -50.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$14.6M -$5.11M -$1.85M -56.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-15
Q3 2023 -$12.7M -$3.11M +$427K +12% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$13.2M -$3.45M -$825K -31.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$12.3M -$2.9M -$233K -8.72% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$12.1M -$3.26M -$633K -24.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-15
Q3 2022 -$11.5M -$3.54M +$1.1M +23.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$12.6M -$2.62M +$1.38M +34.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$13.9M -$2.67M -$1.2M -81.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$12.7M -$2.63M -$1.53M -140% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$11.2M -$4.64M -$3.33M -253% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$7.89M -$4M -$3.09M -338% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$4.8M -$1.47M -$195K -15.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$4.6M -$1.09M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 -$1.31M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$913K Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$1.28M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.